Cartesian reports Descartes-08 Phase 2b MG data: sustained 12-month benefit, Phase 3 on track

Cartesian Therapeutics, Inc.

Average MG-ADL reduction of 4.8 points at Month 12; 83% maintained clinically meaningful response.
In biologic-naive subgroup (n=7): avg 7.1-point MG-ADL reduction, 57% achieved minimum symptom expression (MG-ADL 0-1) at Month 12.
No new safety signals; no CRS or ICANS; supports outpatient administration without lymphodepleting chemo.
Phase 3 AURORA trial on track to dose first patient in Q2 2025; FDA SPA agreement for trial design.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001453687-25-000064
form_type: 8-K
ticker: RNAC
cik: 0001453687
company_name: Cartesian Therapeutics, Inc.
filed_at: 2025-04-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:48.332340+00:00
generated_at: 2026-05-23T18:58:39.572401+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001453687-25-000064
json_url: https://secwatch.observer/filing/0001453687-25-000064.json
markdown_url: https://secwatch.observer/filing/0001453687-25-000064.md
text_url: https://secwatch.observer/filing/0001453687-25-000064.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000064/0001453687-25-000064-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000064/rnac-20250408.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001453687-25-000064

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.